ARMCX3 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- ARMCX3 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100114
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- ARMCX3 antibody Polyclonal Antibodies Primary antibodies
Related genes to: ARMCX3 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- ARMCX3 NIH gene
- Name:
- armadillo repeat containing X-linked 3
- Previous symbol:
- -
- Synonyms:
- ALEX3, GASP6
- Chromosome:
- Xq22.1
- Locus Type:
- gene with protein product
- Date approved:
- 2004-05-10
- Date modifiied:
- 2018-04-26
Related products to: ARMCX3 antibody Polyclonal Antibodies Primary antibodies
Related articles to: ARMCX3 antibody Polyclonal Antibodies Primary antibodies
- Chemotherapy-induced senescence may promote drug resistance and treatment failure. Precise detection and elimination of senescent cancer cells is considered as a novel promising anticancer strategy. However, data on senescence-associated skin cancer cell surface markers as potential therapeutic targets are limited. In the present study, we have established two models of drug-induced senescence in vitro using DNA damaging chemotherapeutics, namely etoposide (0.75-5 µM) and cisplatin (1.25-5 µM), and ten skin cancer cell lines, both melanoma (n = 8, A375, G-361, MM370, SH-4, SK-MEL-1, MeWo, MM127, RPMI-7951) and non-melanoma (n = 2, A431, MCC13), to investigate the levels of 97 cell surface markers. Initial gene expression analysis revealed the increasing tendency in the levels of seven transcripts (ITGA1, ITGA3, VAMP3, STX4, ARMCX3, ULBP2, and PLAUR) and five transcripts (ITGA1, ITGA3, STX4, ARMCX3, and PLAUR) in five etoposide and cisplatin-induced senescent melanoma cell lines, respectively, compared to corresponding proliferating cells. Elevated pools of integrin α1 (ITGA1) were confirmed at mRNA and protein levels in eight drug-induced senescent melanoma cell lines. Similar pattern of changes in integrin α1 levels was not observed in drug-induced senescent non-melanoma skin cancer cells. Analysis using clinical melanoma samples also showed that the levels of ITGA1 and ITGA3 were correlated with the presence of melanoma cells in a section. We document that integrin α1 can be considered as a novel marker of drug-induced senescent melanoma cells. Thus, we postulate that new integrin α1-based targeted therapies can be designed and tested against drug-induced senescent melanoma cells. - Source: PubMed
Publication date: 2025/04/09
Słaby JuliaWnuk MaciejBłoniarz DominikaStec PaulinaSzmatoła TomaszKaznowska EwaReich AdamMoros MaríaLewińska Anna - Epstein-Barr virus (EBV) employs various strategies for long-term survival, including the expression of non-coding RNAs (ncRNAs). This study uncovers and characterizes two novel EBV-encoded ncRNAs, p7 and p8, which are upregulated during lytic reactivation and interact with both viral and host genomes. These ncRNAs bind to cellular RNA transcripts, significantly reducing ARMCX3 mRNA levels, while p8 also influences PTPN6 and RPL24 expressions. Although p7 does not directly bind to LMP1 RNA but both ncRNAs found to downregulate LMP1 expression. Furthermore, these ncRNAs interact with the OriLyt region of EBV genome, promoting viral DNA replication. Functional assays indicate that p7 and p8 enhance cell proliferation and inhibit apoptosis by modulating the p53 pathway and suppressing pro-apoptotic proteins. These findings highlight the role of p7 and p8 in supporting EBV persistence by regulating viral replication, cell survival, and immune evasion, making them promising targets for therapeutic strategies in EBV-related diseases.IMPORTANCEEpstein-Barr virus (EBV) employs diverse strategies for long-term persistence in the host, including the expression of viral non-coding RNAs (ncRNAs) that manipulate key cellular pathways to promote viral replication and immune evasion. This study identifies two novel EBV-encoded ncRNAs, p7 and p8, which are upregulated during lytic reactivation and interact with both viral and host genes to regulate viral DNA replication and promote host cellular survival. By modulating apoptotic and proliferative pathways, p7 and p8 facilitate viral reactivation while promoting host cell survival, highlighting their potential as critical regulators in EBV-driven oncogenesis. This discovery expands our understanding of EBV-host interactions, suggesting p7 and p8 as targets for novel therapeutic strategies in EBV-associated malignancies. - Source: PubMed
Publication date: 2025/04/08
Banerjee SagarikaBose DipayanJohnson SteveLiu JieVirgin HerbertRobertson Erle S - The neural differentiation of dental pulp stem cells (DPSCs) exhibits great potential in the treatment of dental pulp repair and neurodegenerative diseases. However, the precise molecular mechanisms underlying this process remain unclear. This study was designed to reveal the roles and regulatory mechanisms of the armadillo repeat-containing X-linked 3 (ARMCX3) in neural differentiation and inflammatory microenvironment in human DPSCs (hDPSCs). - Source: PubMed
Publication date: 2024/08/28
Zhou QuanyingLei Yi - To investigate the association between mitochondrial events and immune response in periodontitis and related regulatory genes. - Source: PubMed
Publication date: 2024/04/22
Sun XiaoyuWu TongYang ZhanChen ShuhongZhao ZheyuHu ChaomingWu ShengzhuangWu JiayuMao YixinLiu JiefanGuo ChenCao GangXu XiangweiHuang ShengbinLiang Guang - Neurodegenerative diseases are increasingly recognized for their association with oxidative stress, which leads to progressive dysfunction and loss of neurons, manifesting in cognitive and motor impairments. This study aimed to elucidate the neuroprotective role of peroxiredoxin II (Prx II) in counteracting oxidative stress-induced mitochondrial damage, a key pathological feature of neurodegeneration. - Source: PubMed
Publication date: 2024/04/18
Jin Mei-HuaFeng LinXiang Hong-YiSun Hu-NanHan Ying-HaoKwon Taeho